Background The objective was to determine the additional value of pathologic examination using threelevel sectioning and immunocytokeratin (ICK) staining of sentinel lymph node (SN) biopsies in cT1-2N0M0 breast carcinoma patients regarding lymph node staging and eligibility of systemic therapy taking primary tumor characteristics in account. Methods SN slides of 277 patients out of a total group of 961 patients known to have tumor-positive SNs detected by three-level sectioning and ICK staining were re-examined. Haematoxylin-eosin (HE) slide level three was scanned for tumor deposits, and when present, extra capsular extension, maximum tumor diameter and number of positive SNs was noted. In addition, slides of the axillary dissection of non-SNs were reviewed, with determination of metastasis size and number of positive non-SNs. Primary tumor characteristics (grade, diameter, estrogen receptor) were recorded. Results In the single-HE examination, 26 cases SN micrometastasis and 6 macrometastasis were missed, 3 cases of micrometastasis were incorrectly classified as isolated tumor cells, and 9 patients with macrometastasis were misclassified as micrometastasis. In addition, in the tumor-negative single-HE examination, additional axillary lymph node dissection (ALND) revealed 6 cases of non-SN metastasis. Taking primary tumor factors into account for adjuvant systemic therapy, 21 patients would have been denied the choice for systemic therapy if single-HE examination was carried out only. Conclusions Single-HE examination of SN may result in a reduction of locoregional and systemic treatment according to treatment guidelines then current in the Netherlands.
Introduction
The disease status of axillary lymph node metastasis in breast carcinoma is a major prognostic factor, which determines the choice for adjuvant therapy in many cases. Many years after introduction of the sentinel lymph node (SN) method to reduce morbidity of the lymph node staging procedure, no consensus has been reached, which method of pathological examination of the SN is sufficient or which minimum size of lymph node metastasis is of clinical relevance. Until results of large prospective trials such as NSABP-32 are available important practical questions remain controversial.
Weaver [1] advises Hematoxilin & Eosin (HE) stained slides only. Based on Cserni et al [2] , Rutgers [3] concluded that omitting immunocytokeratin (ICK) staining was not as a 'capital offence' when a SN was examined by the pathologist. A recent ASCO Expert Panel review [4] concluded that there was insufficient evidence to recommend ICK for routine evaluation of the SNs.
However, both papers are quite ambiguous: Rutgers admitted that once micrometastasis [i.e., metastasis >= 0.2 mm, but < 2mm] was found in a SN, a 10-20% chance of finding tumor involvement in non-SN could not be ignored. The ASCO Expert Panel recommends ALND for patients with SN micrometastasis regardless of the method of detection.
In addition, relatively few studies have compared in detail 'simple' SN evalution with a single HE slide only versus multilevel sectioning stained with both HE and ICK [5] , [6] , [7] , though choice of technique has a major impact on the fraction of tumor-positive lymph nodes, patient prognosis, choice of adjuvant therapy and laboratory budgets. To our knowledge, no study reported on the impact of SN tumor status (assessed with HE only versus extended examination) on the choice for adjuvant hormonal therapy and/or chemotherapy after taking primary tumor factors into account.
The aim of the present study was to examine retrospectively in a large group of clinically lymph node negative cT1-2 breast carcinoma patients the impact of upstaging by additional pathologic SN examination (i.e., serial sectioning and ICK staining) of the choice for adjuvant hormonal and/or chemotherapy.
Patients and methods
Between January, 2001 and August, 2005, 961 patients with cT1-2N0M0 breast carcinoma underwent an axillary SN biopsy procedure in the Isala klinieken, a large Dutch teaching hospital. Pre-operatively, either a presumptive diagnosis of malignancy was made using the 'triple-method', or malignancy was proven by previous histological diagnosis using thru'-cut or excisional biopsy. The SN procedure was in accordance with Dutch Treatment Standard consisting of preoperative localisation using lymphoscintigraphy with 60-80 MBq 99 mTc nanocolloid as a radioactive tracer and intraoperative dectection with Gammaprobe (Neoprobe, Johnson & Johnson Medical, Hamburg, Germany) and 2 mL of blue dye (Blue Patente V, Guerbet, Aulnay-sur-Bois, France).
Pathological examination was performed in accordance with the Dutch Diagnostic Breast Carcinoma Guidelines 2000 [8] : the lymph node was bisected, submitted in full. Paraffin blocks were sectioned in three levels with approximately 150 micron intervals. Subsequently, both HE and ICK stains were made of sections of each level. The ICK staining made use of the automated stainer NeXes (Ventanamed, Tucson, AZ, USA) with the anti-cytokeratin 7/8 (Neomarkers, Fremont, CA, USA) as the primary antibody. The lymph nodes of the axillary dissection were examined by HE slides of bisected nodes only. The primary tumors were stained for Estrogen Receptor with the 6F11 (Novocastra, Newcastle upon Tyne, UK) antibody on the NeXes autostainer.
Pathologists' reports revealed 277 (29%) patients with tumor-positive SN in patients with invasive adenocarcinoma. The original slides of these SN, the subsequent axillary dissection with the non-SN (if performed) and the primary tumors were reviewed by one pathologist (JEB). The re-examination of the SN consisted of: (a) the presence of tumor in the original HE slide of level three only, and if present, the maximum diameter; (b) the maximum diameter of tumor using all the available slides (i.e., both HE and ICK stained slides of all three levels) (c) the number of tumor-positive SNs and the total number of SNs; (d) presence of extra capsular extension. The non-SNs were reviewed and (a) the maximum diameter of the largest metastasis; (b) number of both tumor-positive and all lymph nodes were noted. Review of the primary tumor comprised: (a) largest diameter; (b) grade using the Bloom-Richardson system and (c) immunopositivity of Estrogen Receptor (positive when >10% nuclear staining present).
For the description of size of the lymph node metastasis the 6th Edition TNM classification was used: (a) isolated tumor cells (ITC): (clumps of) cells £0.2 mm; (b) micrometastasis: > 0.2 mm but no greater than 2 mm; (c) macrometastasis: > 2 mm.
The Dutch Breast Cancer Treatment Guidelines 2004 [9] advises grade one tumors greater than 30 mm, grade two tumors greater than 20 mm, and grade three tumors greater than 10 mm to be treated with adjuvant hormonal and/or chemotherapy in of lymph node negative patients; thus, in these patients the finding of lymph nodes metastasis does not change therapeutic advice as these will already be advised to receive systemic therapy. These guidelines were used to calculate the additional value of three-level sectioning and ICK staining of the SN, and the additional value of ALND in the case of ITCs in the SN. In fact, finding lymph node metastasis in patients already eligible for systemic therapy based on primary tumor characteristics is relevant only for the decision to offer ALND. According to the Guidelines, patients with any lymph node metastasis-ITCs or greater-are eligible for ALND. Patients with lymph node metastasis of 0.2 mm or greater are offered systemic treatment in case primary tumour characteristics would not result in that treatment decision.
Analysis of results was performed using SPSS (v11.5) software. X-square was used for significance calculations, two-sided; significance threshold: p=0.05. Multivariate analysis was done using the forward stepwise method.
Results

Patient characteristics
Of 277 SN-tumor positive patients, three were male and 274 female. Median age was 56 years (range, 30-93 years). Bloom-Richardson tumor grade was 1 in 14%, 2 in 60%, and grade 3 in 25%, respectively. Median tumor size was 20 mm (range, 3-90 mm). ER positivity was noted in 88%. One case with bilateral carcinoma was counted as two procedures. Median SN number was 1 (range, 1-5). Single HE versus three-level SN examination (Table 1) In the single-level HE investigation, 26 patients with a micrometastasis and six with a macrometastasis present in the extended examination were not detected. In addition, 3 of 7 patients with ITC identified in the single HE section had a micrometastasis after the extended assessment. Thus, 35 of 277 SN-tumor positive patients (12.5 %) were understaged if only one HE slide was examined. When only macrometastases are considered, 15 (5.4%) were understaged in the single HE series.
Correlation SN status and Axillary Dissection (Table 2) An axillary dissection was performed in 248 patients with invasive carcinomas (88% of all tumor-positive SNs). The additional 29 patients have chosen not to undergo ALND (21/68 patients without metastasis in single HE but with ITC in the extended SN examination, 1/7 with ITC already in single HE, 5/40 with micrometastasis and 2/157 with macrometastasis) . In the group with no detectable tumor in the single-HE SN, two patients had a micrometastasis in the non-SN, and four patients a macrometastasis. In the small number of patients with ITC's in the single-HE SN no tumor-positive non-SNs were seen. Micrometastasis in the single-HE group gave rise to 10 (of 40) patients with a macrometastasis in the non-SN. Macrometastasis in the SN had a 50% chance (77 of 149) of finding tumor in the additional dissected lymph nodes.
Multivariate analysis of variables predicting tumor in non-SN (Table 3) Multivariate analysis shows a significant contribution of the size of the SN metastasis, the size of the primary tumor and the number of SNs. No significance was present for Estrogen Receptor, age, extra capsular extension or Bloom-Richardson grade.
Upstaging resulting in adjuvant systemic therapy corrected for primary tumor factors Of the 277 patients, a total of 251 were eligible for adjuvant chemotherapy and/or hormonal therapy: 105 patients were eligible based on the finding of micro-or metastasis after single-HE examination of the SN, and a additional 146 patients based of primary tumor characteristics according to current Dutch treatment standards.
In total, 38 patients were upstaged by extended pathological examined in comparison with the single HE method of investigating the SN: 35 patients by the extended pathological examination of the SN (26 micrometastasis, and six macrometastasis [ Table 1 ]), and three by examination of non-SNs in the ALND after ITC were detected in the ICK stained SN slides (1 micrometasis, two macrometastasis) but not in the single level HE slide. In 17 cases adjuvant systemic therapy would have been advised regarding to the Dutch Breast Cancer treatment Guidelines 2004 irrespective of lymph node status. Thus, upstaging of lymph node status relevant for adjuvant systemic therapy occurred in 21 patients.
Discussion
In the present study of 961 patients with a succesful axillary SN procedure, we failed to detect micro-or macrometastasic tumor deposits (i.e., tumor larger than 0.2 mm) in 38 cases (3.9%) after pathologic examination of a single HE section in comparison with three-level sectioning and immunocytokeratin investigation. Substantial upstaging of the lymph node status is to expected, when additional techniques such as multilevel sectioning, ICK staining, and/or molecular biological methods are used (reviewed in Cserni [10] . But, what are the clinical implications of upstaging using other techniques than a single HE slide?
The first clinical implication of the SN procedure concerns the issue of remaining lymph node metastasis after false-negative SN. In our retrospective study, 248 out of 277 patients underwent axillary lymph node dissection (ALND); especially patients with ITC in the SN denied ALND, possibly introducing bias. ALND of the 38 patients upstaged after multilevel sectioning and ICK staining revealed non-SN metastasis in 6 cases (of 47 cases of ALND after ITC found only in ICK stained SNs, 12.5% -see table 2). These findings correspond with the mathematical model presented by Rutgers [3] . However, direct comparison of our findings with the meta-analysis on, which the mathematical model was based is not possible, for these studies report revision of pathologic examination of non-SN or fail to quantify the diameter of the sentinel lymph node metastasis [11] . Recently, Smidt et al [12] concluded that the axillary recurrence rate after negative SN biopsy was 0.25%. In this meta-analysis, most studies had at least multilevel sectioning and immunocytokeratin investigation in some. These findings suggest that an substantial increase in axillary relapse is not to be expected when pathologic examination is based on a single HE section.
Several authors [4] , [13] , [14] mention a rate of 10-20% tumor-positive non-SN in the group with a micrometastasis in the SN after multilevel examination including ICK staining. In our series, the percentage was 32.5% (13/40) after single-HE examination of the SN. This number is substantially higher, because in this group nine patients had a macrometastasis in the SN after multilevel examination including ICK was carried out (Table 1) , with a substantially higher a priori chance of having non-SN metastasis.
The second clinical implication concerns the indication for systemic therapy. In our series, 251 patients would have received such therapy with current Dutch Treatment Standards on the basis of primary tumor characteristics (n = 146) or tumor positivity of the SN based on a three-level sectioning and immunocytokeratin staining on the sentinel node (n = 105). Omitting three-level sectioning and the immunocytokeratin staining of the SN diminished the group of patients with indication for systemic therapy by 8.4% (21/251). We did not determine the number of patients in the group with tumor-negative SN eligible for systemic therapy based of primary tumor characterics. However, it is likely that percentage additional patients of the total group eligible for systemic therapy based on these primary characterics and/or single-HE tumour-positive SN will be lower. In addition, the benefit for systemic therapy is present for only a relatively small fraction of treated patients being between 5 and 10% after 15 years of follow-up [15] . In our study examination of a single HE section of the SN was carried out retrospectively in the group known to contain metastasis, giving rise to a substantial bias. Therefore, if pathogic examination is restricted to single HE slides the fraction metastasis missed can be expected to be higher. We did not differentiate between the examination of three-level HE sections and the effect of additional immunocytokeratin staining. However, the suggested methods [6] , [16] , [17] to read a single HE slide first, and to perform additional sectioning and immunocytokeratin staining is not practical. In our study, a total of 718 (74%) cases would have required additional laboratory callings resulting in increase in workload for the pathologist and delays in reporting.
In conclusion, restriction of pathologic examination of the axillary lymph lymph node in the staging of breast cancer to a single-level HE section results in erroneously omitting additional axillary treatment and systemic therapy. The question of clinical acceptibility is beyond the scope of our report. In fact, only a randomised study with long term follow-up may provide a definite answer. Meanwhile, our data could provide information for the development of standards for pathologic examination of axillary SN.
